Selective protection of non-cancer cells by hypothermia

Anticancer Research

Volumn 22, Issue 6 A, 2002, Pages 3267-3272

  Matijasevic, Zdenka ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Cancer treatment; Cell cycle; Hypothermia; p53

Indexed keywords

ANTINEOPLASTIC AGENT; BROXURIDINE; CYTOTOXIC AGENT; FLUOROURACIL; PROTEIN P53;

ANIMAL CELL; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE; CELL LINE; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; DNA SYNTHESIS; DRUG SELECTIVITY; FIBROBLAST; HUMAN; HUMAN CELL; INDUCED HYPOTHERMIA; LOW TEMPERATURE PROCEDURES; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; TEMPERATURE SENSITIVITY;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; BROMODEOXYURIDINE; CELL CYCLE; CELL SURVIVAL; DNA, NEOPLASM; FIBROBLASTS; FLUOROURACIL; GLIOMA; HL-60 CELLS; HUMANS; HYPOTHERMIA, INDUCED; MICE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036870674     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Houtenbos I, Bracho F, Davenport V, Slack R, van de Ven C, Suen Y, Killen R, Shen V and Cairo MS: Autologous bone marrow transplantation for childhood acute lymphoblastic leukemia: a novel combined approach consisting of ex vivo marrow purging, modulation of multi-drug resistance, induction of autograft vs. leukemia effect, and post-transplant immuno- and chemotherapy (PTIC). Bone Marrow Transplant 27: 145-153, 2001.
2. Martin TG and Linker CA: Autologous stem cell transplantation for acute lymphocytic leukemia in adults. Hematol Oncol Clin North Am 15: 121-143, 2001.
3. Schmitt CA and Lowe SW: Apoptosis and therapy. J Pathol 187: 127-137, 1999.
4. Evan G and Littlewood T: A matter of life and cell death. Science 281: 1317-1322, 1998.
5. Evan GI and Vousden KH: Proliferation, cell cycle and apoptosis in cancer. Nature 411: 342-348, 2001.
6. Gottlieb TM and Oren M: p53 and apoptosis. Semin Cancer Biol 8: 359-368, 1998.
7. Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace Jr AJ, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK, van Osdol WW, Monks AP, Scudiero DA, Sausville EA, Zaharevitz DW, Bunow B, Viswanadhan VN, Johnson GS, Wittes RE and Paull KD: An information-intensive approach to the molecular pharmacology of cancer. Science 275: 343-349, 1997.
8. Kirsch DG and Kastan MB: Tumor-suppressor p53: implications for tumor development and prognosis. J Clin Oncol 16: 3158-3168, 1998.
9. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE and Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810, 1994.
10. Righetti SC, Della Torre G, Pilotti S, Menard S, Ottone F, Colnaghi MI, Pierotti MA, Lavarino C, Cornarotti M, Oriana S, Bohm S, Bresciana GL, Spatti G and Zunino F: A comparative study of p53 gene mutations, protein accumulation, and response to cisplatinbased chemotherapy in advanced ovarian carcinoma. Cancer Res 56: 689-693, 1996.
11. Cordone I, Masi S, Mauro FR, Soddu S, Morsilli O, Valentini T, Vegna ML, Guglielmi C, Mancini F, Giuliacci S, Sacchi A, Mandelli F and Foa R: p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood 91: 4342-4349, 1998.
12. Pardee AB and James LJ: Selective killing of transformed baby hamster kidney (BHK) cells. Proc Natl Acad Sci USA 72: 4994-4998, 1975.
13. Blagosklonny MV and Pardee AB: Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res 61: 4301-4305, 2001.
14. Blagosklonny MV, Robey R, Bates S and Fojo T: Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs. J Clin Invest 105: 533-539, 2000.
15. Blagosklonny MV, Bishop PC, Robey R, Fojo T and Bates SE: Loss of cell cycle control allows selective microtubule-active drug-induced Bcl-2 phosphorylation and cytotoxicity in autonomous cancer cells. Cancer Res 60: 3425-3428, 2000.
16. Matijasevic Z, Snyder JE and Ludlum DB: Hypothermia causes a reversible, p53-mediated cell cycle arrest in cultured fibroblasts. Oncol Res 10: 605-610, 1998.
17. Gailis L: Protection against doxorubicin toxicity in mice by chlorpromazine hypothermia. Res Commun Chem Pathol Pharmacol 53: 319-30, 1986.
18. Hultborn R, Lundgren-Eriksson L, Ottosson-Lonn S, Ryd W and Weiss L: Chlorpromazine-induced hypothermia in tumour-bearing mice, acute cytotoxic drug lethality and long-term survival. Acta Oncol 29: 941-4, 1990.
19. Lundgren-Eriksson L, Palm A, Ryd W, Warnhammar E and Hultborn R: Radio-and chemotoxicity in mice during hypothermia. Anticancer Res 21: 3269-74, 2001.
20. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery Jr CA, Butel JS and Bradley A: Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 356: 215-221, 1992.
21. Wolf D and Rotter V: Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc Natl Acad Sci USA 82: 790-794, 1985.
22. Chen P, Iavarone A, Fick J, Edwards M, Prados M and Israel MA: Constitutional p53 mutations associated with brain tumors in young adults. Cancer Genet Cytogenet 82: 106-115, 1995.
23. Zhan Q, Fan S, Bae I, Guillouf C, Liebermann DA, O'Connor PM and Fornace Jr AJ: Induction of bax by gentoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene 9: 3743-3751, 1994.
24. Jones SN, Sands AT, Hancock AR, Vogel H, Donehower LA, Linke, SP, Wahl GM and Bradley A: The tumorigenic potential and cell growth characteristics of p53-deficient cells are equivalent in the presence or absence of Mdm2. Proc Natl Acad Sci USA 93: 14106- 14111, 1996.
25. Meda P, Chevrier V, Edde B and Job D: Demonstration and analysis of tubulin binding sites on centrosomes. Biochemistry 36: 2550-2558, 1997.
26. Cassimeris LU, Wadsworth P and Salmon ED: Dynamics of microtubule depolymerization in monocytes. J Cell Biol 102: 2023-2032, 1986.